Patients with stadium III melanoma have a risk of local recurrence and distant metastases. In phase III studies, the effectiveness and safety of adjuvant therapies in patients with a resected stage III melanoma is analysed. Based on these studies, adjuvant therapies for stage III melanoma have become available in the Netherlands. To determine the appropriate indication for adjuvant therapy the melanoma must be adequately staged. Clinicians should be informed about the lymph node status in particular. A sentinel node procedure was performed in a minority of melanoma patientsat time of the 2012 Dutch melanoma guideline. Now that adjuvant therapies are approved and available, every patient with stage T1b melanoma or higher and with the desire for adjuvant therapy should be staged with a sentinel node procedure, provided that no enlarged lymph nodes have been found.
Nederlands Tijdschrift voor Dermatologie en Venereologie
Erasmus MC: University Medical Center Rotterdam

Sikkema, B.J. (Barend J.), Gobardhan, P.D, Kuijpers, D.I.M, Den Hoed, D.M. (D. M.), van der Veldt, A.A.M, & ten Tije, A.J. (2020). Nieuwe aanvullende behandeling voor stadium iii-melanoom. Nederlands Tijdschrift voor Dermatologie en Venereologie, 30(3), 6–8. Retrieved from